SUPPLEMENTARY DATA



Supp. Fig. 1 Differential analysis of BALF cytospins. (A) Representative cytospins of BALF cells obtained from control (tamoxifen treated SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice) and SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice 3 d, 7 d, and 2 wk following intraperitoneal tamoxifen administration (250 mg/kg). **(B)** Relative quantitation of the changes in macrophage (top left), neutrophils (bottom left), lymphocyte (top right) and eosinophils (bottom right) obtained from cytospin differential analysis of control (tamoxifen treated SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice) and SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice 3 d, 7 d, and 2 wk following intraperitoneal tamoxifen administration (250 mg/kg). Data is represented as mean ± SEM (N=4-18). Differences between groups were compared using one-way ANOVA, using Tukey post-hoc test. * $p < 0.05$ compared to control SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice SP-C$^{I73T/I73T}$ER$^{-/-}$ by ANOVA, using Tukey post-hoc test.



Supp. Fig. 2. Temporal changes in BALF and tissue macrophage, neutrophil, and eosinophil and lymphocyte populations. (A) Time dependent changes in tissue macrophages, monocytes, neutrophils and eosinophils collected from control (tamoxifen treated SP-$C^{WT/WT}Flp^{+/+}$ or oil treated SP-$C^{I73T/I73T}Flp^{+/-}$ mice) and SP-$C^{I73T/I73T}Flp^{+/-}$ mice 3 days, 7 days, and 2 weeks following intraperitoneal tamoxifen administration (250 mg/kg). **(B)** Time course of the changes in BALF and tissue lymphocytes collected from control (tamoxifen treated SP-$C^{WT/WT}Flp^{+/+}$ or oil treated SP-$C^{I73T/I73T}Flp^{+/-}$ mice) and SP-$C^{I73T/I73T}Flp^{+/-}$ mice 3 days, 7 days, and 2 weeks following intraperitoneal tamoxifen administration (250 mg/kg).



Supp. Fig. 3. Systemic monocyte depletion with clodronate liposomes does not affect alveolar macrophage and neutrophil numbers in BALF and tissue of SP-C^{I73T} mice. (A) Changes in absolute counts of BALF SigF^{+}CD11b^{-} macrophages and **(B)** Ly6G^{+} neutrophils from control (tamoxifen treated SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice) and SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice 3 d, 7 d and 2 weeks following intraperitoneal tamoxifen (250 mg/kg) and intravascular clodronate (150 µg/kg, 2 h post tamoxifen injection) administration. Data is represented as mean ± SEM (N=3-8). * $p < 0.05$ compared to control SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice SP-C$^{I73T/I73T}$ER$^{-/-}$ by One-Way ANOVA, using Tukey post-hoc test.



Supp. Fig. 4. Intravascular monocyte depletion with clodronate liposomes does not affect BALF cell gene expression of SP-C^{I73T} mice. RT-qPCR analysis of BALF cells collected from control (tamoxifen treated SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice) and SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice 2 wk following intraperitoneal tamoxifen (250 mg/kg) and intravascular clodronate (150 µg/kg, 2 h post tamoxifen injection) administration for markers associated with **(A)** recruitment (*Mcp1*), **(B)** pro-inflammatory (*Nos2*) and **(C-D)** anti-inflammatory (*Arg1* and *Fizz1*) activation. Data is represented as mean ± SEM (N=3-5). * $p < 0.05$ compared to control SP-C$^{WT/WT}$Flp$^{+/+}$ or oil treated SP-C$^{I73T/I73T}$Flp$^{+/-}$ mice SP-C$^{I73T/I73T}$ER$^{-/-}$ by One-Way ANOVA, using Tukey post-hoc test.